// App-Quantinova.ai

8002 : Phase 1/2 trial of ixazomib, cyclophosphamide, and dexamethasone for newly diagnosed multiple myeloma (NDMM).

Researchers

Presenter

  • Martha Lacy

Principal Investigators

  • Betsy LaPlant

  • Alese Halvorson

  • Francis Buadi

  • Nelson Leung

  • Ronald S. Go

  • David Dingli

  • Prashant Kapoor

  • Morie A. Gertz

  • Yi Lin

  • Angela Dispenzieri

  • Yi Lisa Hwa

  • Amie Fonder

  • Rafael Fonseca

  • Suzanne R. Hayman

  • A. Keith Stewart

  • Joseph Mikhael

  • S. Vincent Rajkumar

  • Shaji Kumar

Medical Centers

  • Mayo Clinic, Rochester, MN

  • Mayo Clinic, Scottsdale, AZ

  • Division of Medical Oncology, Mayo Clinic, Rochester, MN

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Ixazomib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved